{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"CIRB\/COG AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in\nCombination with Nivolumab (NSC# 748726, IND# 125462),a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged &#8805;1 to <31 Years Old with First Relapse","item":"https:\/\/www.regionalcancercare.org\/trials\/cirb-cog-aall1821-a-phase-2-study-of-blinatumomab-nsc-765986-ind-125462-incombination-with-nivolumab-nsc-748726-ind-125462a-checkpoint-inhibitor-of-pd-1-in-b-all-patients-aged-1-t\/#breadcrumbitem"}]}